- ISSN: 2212-697X
- E-ISSN: 2212-6988
HTML
-
f Advancements in Cancer Therapeutics: Emerging Agents and Combination Strategies in Drug Discovery
- Source: Clinical Cancer Drugs, Volume 11, Issue 1, Jan 2025, E2212697X361870
-
- 15 Oct 2024
- 04 Dec 2024
- 14 Jan 2025
Abstract
In the last few years, there have been significant advances in cancer agent research, most of which entered clinical trials after succeeding in initial preclinical studies. Here, we discuss successful accomplishments in the promising approaches of targeted therapies, immunotherapies, and combination therapies. The development in these areas includes sotorasib - targeting the mutation of KRAS for lung and pancreatic cancer and pembrolizumab - an immune checkpoint inhibitor for melanoma therapy; the latter has been synergistic with chemotherapy. In addition, exciting results emerge from trials with the DNA damage repair inhibitor olaparib in BRCA-mutated cancers and the tyrosine kinase inhibitor osimertinib for EGFR-mutant lung cancer. Bevacizumab continues to establish itself as an evolving therapy in colorectal cancer, and niraparib enters Phase III in ovarian cancer. New combinations will include alpelisib and PD-1 inhibitors and nanoparticle-based Abraxane for triple-negative breast cancers leading toward precision medicine. These would improve the survival rates and quality of life in patients with advanced or refractory malignancies.
